NCT05234606 - A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | Biotech Hunter

Timeline

Start Date

March 31, 2022

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions

Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckHormone Receptor-positive/HER2-negative Breast Cancer

Interventions

DRUG

SBT6290

Escalating doses by subcutaneous (SC) injection in 21-day cycles

DRUG

SBT6290

Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles

DRUG

pembrolizumab

200 mg via intravenous (IV) injection in 21-day cycles